SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (279)3/18/1999 2:37:00 PM
From: JOEBT1  Read Replies (2) of 3158
 
Peter--You seem to bemoan the ineptness of large Pharma in acquiring biotech companies. In fact, of course, they have been very efficient in the acquistion of technology of small biotechs. They form a partnership with milestone payments contingent on success and " acquire" the technology they think most promising. Thus they avoid the negative bottomline burden associated with acquiring the company and get rights to the most promising technologies at "least cost". The companies most ripe for acquistion are those that are profitable or close to it--and! they have the rights to their technologies and have not farmed them to a host of partners. Agouron is a good example of an acquistion candidate--MLNM is probably not a good candidate. Glia may be attractive but they are diminishing their value with a second pipeline which will suck up profits.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News